TY - JOUR
T1 - ψ and χ Angle Constrains at the C-Terminus Trp Position of the Melanotropin Tetrapeptide Ac-His- d -Phe-Arg-Trp-NH2Lead to Potent and Selective Agonists at hMC1R and hMC4R
AU - Zhou, Yang
AU - Mowlazadeh Haghighi, Saghar
AU - Sawyer, Jonathon R.
AU - Hruby, Victor J
AU - Cai, Minying
N1 - Funding Information:
These studies were supported in part by grants from the U.S. Public Health Service, National Institutes of Health, Grants DK017420 and GM 108040, and a proof-of-concept grant from the University of Arizona Tech Launch Transfer.
Publisher Copyright:
© 2023 American Chemical Society.
PY - 2023/5/25
Y1 - 2023/5/25
N2 - Melanocortin receptors (MCRs) are a family of G protein-coupled receptors that regulate important physiological functions. Yet, drug development targeting MCRs is hindered by potential side effects due to a lack of receptor subtype-selective ligands with bioavailability. Here, we report novel synthetic pathways to introduce ψ and χ angle constraints at the C-terminus Trp position of the nonselective prototype tetrapeptide agonist Ac-His-d-Phe-Arg-Trp-NH2. With these conformational constraints, peptide 1 (Ac-His-d-Phe-Arg-Aia) shows improved selectivity at hMC1R, with an EC50 of 11.2 nM for hMC1R and at least 15-fold selectivity compared to other MCR subtypes. Peptide 3 (Ac-His-pCF3-d-Phe-Arg-Aia) is a potent and selective hMC4R agonist with an EC50 of 4.1 nM at hMC4R and at least ninefold selectivity. Molecular docking studies reveal that the ψ and χ angle constraints force the C-terminal Aia residue to flip and interact with TM6 and TM7, a feature that we hypothesize leads to the receptor subtype selectivity.
AB - Melanocortin receptors (MCRs) are a family of G protein-coupled receptors that regulate important physiological functions. Yet, drug development targeting MCRs is hindered by potential side effects due to a lack of receptor subtype-selective ligands with bioavailability. Here, we report novel synthetic pathways to introduce ψ and χ angle constraints at the C-terminus Trp position of the nonselective prototype tetrapeptide agonist Ac-His-d-Phe-Arg-Trp-NH2. With these conformational constraints, peptide 1 (Ac-His-d-Phe-Arg-Aia) shows improved selectivity at hMC1R, with an EC50 of 11.2 nM for hMC1R and at least 15-fold selectivity compared to other MCR subtypes. Peptide 3 (Ac-His-pCF3-d-Phe-Arg-Aia) is a potent and selective hMC4R agonist with an EC50 of 4.1 nM at hMC4R and at least ninefold selectivity. Molecular docking studies reveal that the ψ and χ angle constraints force the C-terminal Aia residue to flip and interact with TM6 and TM7, a feature that we hypothesize leads to the receptor subtype selectivity.
UR - http://www.scopus.com/inward/record.url?scp=85159623373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85159623373&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.2c01794
DO - 10.1021/acs.jmedchem.2c01794
M3 - Article
C2 - 37133411
AN - SCOPUS:85159623373
SN - 0022-2623
VL - 66
SP - 6715
EP - 6724
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 10
ER -